Ignite Creation Date:
2025-12-25 @ 2:51 AM
Ignite Modification Date:
2026-01-05 @ 1:01 AM
Study NCT ID:
NCT07281833
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2025-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Sponsor:
West German Study Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-03
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-19
First Submit QC Date:
None
Study First Post Date:
2025-12-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-15
Last Update Post Date Type:
ESTIMATED